NSR:乙肝病毒相关性肝细胞癌的肿瘤微环境

2014-10-07 王小凡 《国家科学评论》

HBV调节肿瘤微环境中细胞组分的活性 肝细胞癌(hepatocellular carcinoma,HCC)是世界上第五大常见恶性肿瘤,为癌症死亡第三大原因。 与很多癌症不同, 肝细胞癌的发生与慢性肝脏疾病进程密切相关。乙型肝炎病毒(hepatitis B virus,HBV)感染是HCC最重要的病因之一,HBV诱发肝癌通常伴随或继发于长期的慢性肝炎(chronic he


HBV调节肿瘤微环境中细胞组分的活性

肝细胞癌(hepatocellular carcinoma,HCC)是世界上第五大常见恶性肿瘤,为癌症死亡第三大原因。 与很多癌症不同, 肝细胞癌的发生与慢性肝脏疾病进程密切相关。乙型肝炎病毒(hepatitis B virus,HBV)感染是HCC最重要的病因之一,HBV诱发肝癌通常伴随或继发于长期的慢性肝炎(chronic hepatitis)、炎症反应(inflammation)和肝硬化(cirrhosis)。近年的研究表明,除了直接影响肝细胞癌变之外,HBV感染 还通过调控肿瘤微环境来影响肝细胞癌的发生,发展和转移。

美国杜克大学医学院王小凡教授在《国家科学评论》最新发表综述文章“乙型肝炎病毒相关性肝细胞癌的肿瘤微环境”(http://nsr.oxfordjournals.org/content/1/3/396.full),详尽阐述了近年来发现的HBV感染相关肝细胞癌肿瘤微环境中的细胞组分、非细胞组分及其相关作用机制。

该文中提到,HBV感染相关肝细胞癌肿瘤微环境中的细胞成分包括肿瘤浸润性淋巴细胞(Tumor-infiltrating lymphocytes)、树突状细胞(Dendritic cells,DCs)、巨噬细胞和库夫氏细胞Macrophages and Kupffer cells)、自然杀伤细胞(Natural Killer cells,NK cells)、肿瘤相关成纤维细胞(Carcinoma-associated fibroblasts ,CAFs)和肝脏星状细胞(Hepatic stellate cells,HSCs)及内皮细胞(Endothelial cells)等;非细胞组分主要有细胞因子(Cytokines)和趋化因子(Chemokines),生长因子(Growth factors)和其他可溶性蛋白(soluble proteins),微小RNA(microRNAs)及物理免疫微环境等。

王小凡教授指出,肝细胞癌形成背景复杂,肿瘤微环境还会随着肝细胞癌的发生、发展及转移等过程呈现出高度的动态变化和更为复杂的交互作用系统。HBV感染对于肝细胞癌微环境中细胞组分及非细胞组分的调控起着关键作用,可显著影响肝细胞癌的发展和预后。阐明这一交互系统中的主要成分及作用机制,分析动态变化的肿瘤微环境的共性及不同之处,对于发展更加有效、针对性更强的治疗方法意义重大。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1863228, encodeId=d266186322869, content=<a href='/topic/show?id=c0b68135561' target=_blank style='color:#2F92EE;'>#肝细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81355, encryptionId=c0b68135561, topicName=肝细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Fri Nov 14 11:22:00 CST 2014, time=2014-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1837151, encodeId=c330183e15164, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Sat Jul 18 11:22:00 CST 2015, time=2015-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1978396, encodeId=ecba19e8396f3, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Fri Jun 05 11:22:00 CST 2015, time=2015-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=12009, encodeId=dacb12009c9, content=对啊,说的好简单, beContent=null, objectType=article, channel=null, level=null, likeNumber=127, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=10.20.194.67, createdTime=Tue Oct 07 11:44:00 CST 2014, time=2014-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=12004, encodeId=b2a812004a8, content=好象也没讲清楚吧, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=dide, createdTime=Tue Oct 07 09:36:00 CST 2014, time=2014-10-07, status=1, ipAttribution=)]
    2014-11-14 xjy02
  2. [GetPortalCommentsPageByObjectIdResponse(id=1863228, encodeId=d266186322869, content=<a href='/topic/show?id=c0b68135561' target=_blank style='color:#2F92EE;'>#肝细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81355, encryptionId=c0b68135561, topicName=肝细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Fri Nov 14 11:22:00 CST 2014, time=2014-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1837151, encodeId=c330183e15164, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Sat Jul 18 11:22:00 CST 2015, time=2015-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1978396, encodeId=ecba19e8396f3, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Fri Jun 05 11:22:00 CST 2015, time=2015-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=12009, encodeId=dacb12009c9, content=对啊,说的好简单, beContent=null, objectType=article, channel=null, level=null, likeNumber=127, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=10.20.194.67, createdTime=Tue Oct 07 11:44:00 CST 2014, time=2014-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=12004, encodeId=b2a812004a8, content=好象也没讲清楚吧, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=dide, createdTime=Tue Oct 07 09:36:00 CST 2014, time=2014-10-07, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1863228, encodeId=d266186322869, content=<a href='/topic/show?id=c0b68135561' target=_blank style='color:#2F92EE;'>#肝细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81355, encryptionId=c0b68135561, topicName=肝细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Fri Nov 14 11:22:00 CST 2014, time=2014-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1837151, encodeId=c330183e15164, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Sat Jul 18 11:22:00 CST 2015, time=2015-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1978396, encodeId=ecba19e8396f3, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Fri Jun 05 11:22:00 CST 2015, time=2015-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=12009, encodeId=dacb12009c9, content=对啊,说的好简单, beContent=null, objectType=article, channel=null, level=null, likeNumber=127, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=10.20.194.67, createdTime=Tue Oct 07 11:44:00 CST 2014, time=2014-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=12004, encodeId=b2a812004a8, content=好象也没讲清楚吧, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=dide, createdTime=Tue Oct 07 09:36:00 CST 2014, time=2014-10-07, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1863228, encodeId=d266186322869, content=<a href='/topic/show?id=c0b68135561' target=_blank style='color:#2F92EE;'>#肝细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81355, encryptionId=c0b68135561, topicName=肝细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Fri Nov 14 11:22:00 CST 2014, time=2014-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1837151, encodeId=c330183e15164, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Sat Jul 18 11:22:00 CST 2015, time=2015-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1978396, encodeId=ecba19e8396f3, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Fri Jun 05 11:22:00 CST 2015, time=2015-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=12009, encodeId=dacb12009c9, content=对啊,说的好简单, beContent=null, objectType=article, channel=null, level=null, likeNumber=127, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=10.20.194.67, createdTime=Tue Oct 07 11:44:00 CST 2014, time=2014-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=12004, encodeId=b2a812004a8, content=好象也没讲清楚吧, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=dide, createdTime=Tue Oct 07 09:36:00 CST 2014, time=2014-10-07, status=1, ipAttribution=)]
    2014-10-07 10.20.194.67

    对啊,说的好简单

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1863228, encodeId=d266186322869, content=<a href='/topic/show?id=c0b68135561' target=_blank style='color:#2F92EE;'>#肝细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81355, encryptionId=c0b68135561, topicName=肝细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Fri Nov 14 11:22:00 CST 2014, time=2014-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1837151, encodeId=c330183e15164, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Sat Jul 18 11:22:00 CST 2015, time=2015-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1978396, encodeId=ecba19e8396f3, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Fri Jun 05 11:22:00 CST 2015, time=2015-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=12009, encodeId=dacb12009c9, content=对啊,说的好简单, beContent=null, objectType=article, channel=null, level=null, likeNumber=127, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=10.20.194.67, createdTime=Tue Oct 07 11:44:00 CST 2014, time=2014-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=12004, encodeId=b2a812004a8, content=好象也没讲清楚吧, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=dide, createdTime=Tue Oct 07 09:36:00 CST 2014, time=2014-10-07, status=1, ipAttribution=)]
    2014-10-07 dide

    好象也没讲清楚吧

    0

相关资讯

EASL 2014:乙肝和戊肝专题报道

  4月12日下午,国际肝病学会候任主席,亚太地区肝病学会前任主席、中华医学会肝病学分会前任主任委员贾继东教授和意大利布鲁内托(Brunetto)教授共同主持了乙肝和戊肝专题会议,共8位代表先后报告了他们的最新研究结果。   关键词:聚乙二醇干扰素λ1a与聚乙二醇干扰素α2a   中国香港中文大学陈力元教授代表来自亚洲、欧洲和北美的临床研究者报道了聚乙二醇干扰素λ1a治疗乙肝

Clin Gastroenterol Hepatol:抗病毒或降乙肝患者肝癌风险

   近日,刊登在国际杂志Clinical Gastroenterology and Hepatology上的一篇研究论文中,来自亚特兰大疾病预防控制中心的研究人员通过研究发现,抗病毒疗法或许可以成功抑制乙型肝炎病人发展为肝细胞癌(肝癌的一种形式)。 文章中,研究者对超过2600名运用抗病毒疗法治疗的乙肝病毒患者进行分析研究,进行长达5年的抗病毒疗法后患者患肝细胞

Hepatology:长期恩替卡韦可有效治疗慢乙肝原发性无应答者

乙肝病毒复制水平的慢性升高将会增加肝纤维化和肝癌风险,且与肝脏相关疾病的死亡有关。因此,慢乙肝的治疗目的是持久地抑制病毒复制,减少肝损伤。存在着大量的证据显示,治疗早期的HBV DNA反应强烈预示了长期的病毒学结果,因此广泛推荐原发性无应答者和部分病毒反应者在早期调整治疗方案。 上述策略大部分是基于低效的核苷(酸)类似物(NAs)如拉米夫定和替比夫定之上的。事实上,无论基线HBV DNA水平和H

Arrowhead治疗乙肝RNAi药物临床研究取得进展

总部位于加利福尼亚州帕萨迪纳市的生物技术公司Arrowhead最近宣布公司开发的用于治疗乙肝的RNAi药物ARC-520取得良好研究数据。该消息一经披露,公司股价应声上扬。ARC-520采用了Arrowhead公司独有的Dynamic Polyconjugates输送系统。其原理是通过RNA干扰封闭乙肝病毒某些蛋白的表达,造成病毒无法增殖,然后再利用机体的免疫系统对剩余病毒进行清除。

EASL 2014:聚乙二醇干扰素LAMBDA 早期抗HBV疗效优于ALFA

HBeAg+慢乙肝患者的中期(24周)治疗结果表明,聚乙二醇干扰素Lambda-1a 比聚乙二醇干扰素Alfa-2a显示出更强的早期病毒学/血清学反应和更好的耐受性。该研究为治疗24周后的报告结果。 成人HBeAg+,干扰素初治患者(HBV-DNA> 105IU/mL,ALT > 1×ULN [ULN = 47U/ L]),随机(1:1)分配接受每周180ug的LAMBDA或Alfa治

Gut:恩替卡韦不能消除乙肝患者的肝细胞癌风险

近期一项研究显示,使用恩替卡韦治疗慢性乙肝的患者,仍具有发生肝细胞癌(HCC)的风险。相关结果7月10日在线发表于Gut杂志。这项研究还揭示,基于人口统计学、临床和病毒学特征制定的HCC风险评分的预测作用不加,尤其是在高加索人群中。研究的作者认为,这是一项重要的研究。恩替卡韦是一种非常强效的抗病毒制剂,可高效抑制病毒、压制病情、并使疾病缓解,提示其具有减少炎症反应、减少纤维化和减轻硬化的作用。而研